葡萄糖皮质类药物使用和败血症28天死亡率:MIMIC-III数据库的回顾性分析
Dongsheng Yang1, Chunfa Jiang1, Zhangzhang Xiao2
1Department of Geriatrics, Houjie Hospital of Dongguan, Dongguan, Guangdong, 523945, China.
Respiratory medicine
|October 13, 2025
概括
在败血症管理中使用葡萄糖皮质类药物显示了相互矛盾的结果. 虽然一些分析表明生存益处,但另一些分析表明死亡风险增加,强调需要进一步研究.
科学领域:
- 临界护理医学 临界护理医学
- 药理学 药理学是指药理学的学科.
- 流行病学 流行病学
背景情况:
- 葡萄糖皮质激素在败血症治疗中的作用仍然存在争议.
- 败血症是一种危及生命的疾病,需要有效的治疗策略.
研究的目的:
- 为了研究葡萄糖皮质体剂和28天死亡率在重症监护室 (ICU) 患有败血症的患者之间的关联.
- 用各种统计模型分析葡萄糖皮质体使用对败血症结局的影响.
主要方法:
- 来自MIMIC-III数据库的成年败血症患者的回顾性分析.
- 暴露被定义为在ICU停留期间全身使用葡萄糖皮质激素.
- 采用原始物流回归,反向概率加权考克斯模型,时间依赖的考克斯回归和零碎的考克斯模型.
主要成果:
- 粗略的后勤回归显示,使用葡萄糖皮质激素的28天死亡率增加 (OR=1.27).
- 反向概率加权的考克斯模型表明死亡风险降低 (HR=0.88).
- 时间依赖和零碎的考克斯模型始终表明死亡风险增加 (HR=1.22和HR=1.26,分别).
结论:
- 分析策略在葡萄糖皮质体对败血症死亡率的影响方面产生了异质的结果.
- 权重模型表明潜在的生存益处,而其他分析表明危害增加.
- 预期试验至关重要,以确定葡萄糖皮质类药物在败血症管理中的作用.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
434
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
434
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
178
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
178
Hypoglycemia and Glucagon
830
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
830
Acute Respiratory Failure-III
781
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
781
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
1.5K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.5K
Acute Respiratory Failure-II
1.0K
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
1.0K


